Company intelligence / Profile preview

Sinotau Pharmaceutical Group

Beijing, China
Ownership
Private
Development stage
Commercial
01

Overview

Sinotau has successfully commercialized Florbetaben F 18 injection (Neuraceq®/欧韦宁®), the first amyloid PET tracer approved in China for Alzheimer's disease diagnosis. The company has over 20 novel products in different development stages, including Phase 3 trials for Florquinitau F18 for mild cognitive disorders and Phase 2/3 trials for Lutetium Dotatate LU-177 for neuroendocrine tumors.

Therapeutic areas
OncologyCardiovascularNeurology
Modalities
Diagnostic radiopharmaceuticalsTherapeutic radiopharmaceuticalsSmall molecule drugsPeptide Conjugate Radionuclide
Industry
Biotech
02

Drug pipeline

20 assets

lutetium Lu-177 XT033

2

19 more assets in the full pipeline.

Request access →
03

Partnerships

Blue Earth Diagnostics LtdLife Molecular ImagingIsotopia Molecular ImagingMeilleur (joint venture)Lantheus

Beyond the preview

Go deeper on Sinotau Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinotau Pharmaceutical Group.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call